The large therapeutic market for chronic obstructive pulmonary disease (COPD), a disease that is closely associated with smoking, continues to expand and is expected to grow from approximately $15…
Idiopathic pulmonary fibrosis (IPF), although a rare disease, is one of the most common interstitial lung diseases (ILDs); IPF is characterized by irreversible loss of lung function leading to high…
The COPD treatment algorithm continues to evolve, with changing recommendations on the use of ICS s, LABA / ICS FDC s, and LABA / LAMA FDC s. This study reveals which therapies are prescribed first…
Pulmonary hypertension (PH), particularly pulmonary arterial hypertension (PAH), is a rare but life-threatening disorder. Commercial interest in PH/PAH has increased recently due to significant…
Pulmonary hypertension (PH) is a devastating disease, for which there is no cure. Despite the rarity of the disease, the potential commercial rewards from drugs approved for it are considerable,…
The large therapeutic market for chronic obstructive pulmonary disease (COPD), a disease that is closely associated with smoking, continues to expand and is expected to grow from approximately $15…
Scleroderma (systemic sclerosis [SSc]) is a rare progressive autoimmune disease characterized by skin fibrosis and varying degrees of vasculopathy manifesting as Raynaud’s disease and, often,…
Idiopathic pulmonary fibrosis (IPF), although a rare disease, is one of the most common interstitial lung diseases (ILDs) and is characterized by irreversible loss of lung function leading to high…
This detailed, expanded analysis explores key access and reimbursement topics in the rare disease space in the United States, such as the approaches managed care organizations take to control both…
Despite the recent launches of several new therapies, adding to the range of pharmacotherapies available for treating PAH, and contributing to the complexity of the PAH treatment algorithm, a…
The U.S. therapy market for chronic obstructive pulmonary disease (COPD) is becoming increasingly crowded. As more therapies with similar clinical profiles launch and the threat of generic versions…
The chronic obstructive pulmonary disease (COPD) market is becoming increasingly crowded, but significant unmet need remains due to the lack of a disease-modifying therapy. In recent years, several…
Last Updated 14 December 2015 The large therapeutic market for chronic obstructive pulmonary disease (COPD), a disease that is closely associated with smoking, continues to expand. The prevalence…
For the estimated 9 million patients diagnosed with chronic obstructive pulmonary disease (COPD) in the United States, there are multiple prescription therapies that are available for treating the…
Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), represents a significant public health and financial burden. The expansion of the treatment labels…